Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
ALPS Medical Breakthroughs ETF (SBIO): Exploring Opportunities in Clinical-Stage Biotech

ALPS Medical Breakthroughs ETF (SBIO): Exploring Opportunities in Clinical-Stage Biotech

Key Takeaways

  • Interest-rate sensitivity is a defining driver. Small- and mid-cap biotech is a long-duration asset class, so future outlook depends heavily on the Federal Reserve's policy path and real-rate trends.
  • Clinical trial milestones are the primary micro-catalyst. Because SBIO holds companies with drugs in Phase II or Phase III trials, upcoming data readouts and FDA decisions can move the fund independently of broader market trends.
  • Portfolio exposure is nearly all healthcare. With roughly 100% of assets in biotechnology and pharmaceuticals, sector outlook and pipeline productivity, not diversification, drive the fund's trajectory.
  • M&A remains a recurring tailwind. Large pharmaceutical companies' need to replenish pipelines supports demand for the clinical-stage innovators SBIO owns.
  • Structural risk is elevated. High volatility, concentration in early-stage names, and sensitivity to funding conditions make this a high-beta expression of the biotech theme.

Understanding SBIO's Portfolio and Strategy

The ALPS Medical Breakthroughs ETF (SBIO) is a passively managed fund that seeks to track the S-Network Medical Breakthroughs Index. The index holds small- and mid-cap U.S.-listed biotechnology and pharmaceutical companies that have at least one drug in Phase II or Phase III clinical trials, with constituent market capitalizations generally between $200 million and $5 billion. The fund carries a net expense ratio of 0.50% and manages roughly $200 million in assets, positioning it as a niche, thematic vehicle rather than a broad healthcare allocation.

Portfolio exposure is overwhelmingly healthcare, with biotechnology representing the largest industry weight and pharmaceuticals a secondary but meaningful component. Top holdings have recently included Crinetics Pharmaceuticals (CRNX), Apogee Therapeutics (APGE), CG Oncology (CGON), Oruka Therapeutics (ORKA), Travere Therapeutics (TVTX), and Edgewise Therapeutics (EWTX), with the top ten names accounting for roughly 30% of assets. Geographic exposure is primarily domestic, with more than 80% of assets in U.S.-listed companies and modest positions in Europe and Asia.

Structurally, SBIO is best understood as a clinical-stage innovation basket. Its future performance potential hinges less on current earnings and more on the ability of its holdings to advance drug candidates toward regulatory approval and commercialization. This means the fund's trajectory is driven by binary, event-oriented catalysts that can produce sharp moves in either direction. I also checked this using Tickeron’s AI Screener to see how the holdings compare within the broader biotech space.

Upcoming Catalysts to Watch

Several forward-looking developments could shape SBIO's path. First, FDA approval decisions and advisory committee meetings for Phase III assets held across the portfolio are high-impact events, since an approval can dramatically re-rate a company's valuation.

Second, monetary policy is a macro catalyst. Because clinical-stage companies generate little near-term cash flow, their valuations are particularly sensitive to discount rates. A sustained decline in interest rates would tend to support the long-duration biotech trade, while a re-acceleration of inflation that keeps rates elevated could pressure valuations.

Third, M&A activity is a recurring theme. Large pharmaceutical firms facing patent expirations often acquire clinical-stage innovators, and deal premiums can lift both individual holdings and sentiment across the index.

Fourth, policy and regulatory developments, including drug-pricing reform under the Inflation Reduction Act and shifting FDA posture on accelerated approvals, could alter the economics of pipeline development. Finally, fund flows into healthcare and biotech ETFs reflect investor appetite for risk; sustained inflows would reinforce the sector, while outflows could amplify downside volatility.

Macro and Sector Perspectives

The macro outlook is central to SBIO's trajectory because biotech is among the most interest-rate-sensitive corners of the equity market. In a declining-rate environment, the present value of future drug revenue rises, historically benefiting clinical-stage names. Conversely, higher-for-longer rates raise financing costs and reduce the appeal of cash-burning companies relative to profitable large caps.

The broader healthcare sector outlook remains supported by structural demand from aging demographics and continued innovation in areas such as oncology, rare disease, immunology, and metabolic therapies. Within SBIO's portfolio, many holdings target precisely these high-growth therapeutic categories. However, sector cycles in biotech can be pronounced: periods of robust capital availability and IPO activity tend to coincide with outperformance, while risk-off environments compress valuations across the index.

On a global basis, currency movements have a limited but non-zero effect given the fund's small European and Asian weightings. The dominant macro forces are domestic: U.S. interest rates, inflation trends, healthcare policy, and the availability of venture and follow-on financing that sustains the innovation pipeline the index seeks to capture.

Long-Term Structural Trends

Over a longer horizon, SBIO's structural positioning reflects several durable themes. An aging global population continues to expand the addressable market for innovative therapeutics, while advances in genetic medicine, precision oncology, and AI-assisted drug discovery are broadening the pipeline of addressable diseases. These trends support a long-term demand story for the clinical-stage innovators SBIO holds.

At the same time, market-structure changes matter. The relative scarcity of new public biotech listings can influence the index's composition and quality, while the strategic appetite of large pharmaceutical acquirers remains a structural demand source for late-stage assets. Interest-rate cycles will continue to ebb and flow, but the long-term direction of innovation spending and healthcare demand provides a constructive backdrop, even as the fund's high volatility and binary clinical risk require a patient, risk-aware approach. As with any thematic ETF, the macro outlook and the sector's financing cycle will remain as important to future returns as the science itself.

Leveraging Tickeron’s AI Tools in Practice

One tool I’ve found useful for gauging near-term momentum in holdings like those in SBIO is Tickeron’s Trend Prediction Engine. It applies pattern recognition and historical data to flag potential bullish, bearish, or sideways moves over the coming weeks or months. Pairing these signals with the fundamental catalysts discussed above has helped me add a timing dimension to an otherwise event-driven approach. From what I see, this kind of data layer can be particularly valuable when monitoring binary clinical outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SBIO

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


SBIO's RSI Indicator climbs out of oversold territory

The RSI Oscillator for SBIO moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In 27 of the 29 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on SBIO as a result. In 75 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for SBIO just turned positive on October 20, 2026. Looking at past instances where SBIO's MACD turned positive, the stock continued to rise in 46 of 51 cases over the following month. The odds of a continued upward trend are 90%.

Following a +9.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in 277 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.

The Aroon Indicator entered an Uptrend today. In 211 of 230 cases where SBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 63 cases where SBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.

SBIO moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

SBIO broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Sarepta Therapeutics (NASDAQ:SRPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF (SBIO) ETF is 2.08B. The market cap for tickers in the group ranges from 63.25M to 6.81B. ORKA holds the highest valuation in this group at 6.81B. The lowest valued company is TENX at 63.25M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was -0%. For the same ETF, the average monthly price growth was 9%, and the average quarterly price growth was 4%. DCTH experienced the highest price growth at 38%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF (SBIO) ETF was -12%. For the same stocks of the ETF, the average monthly volume growth was -14% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 44
P/E Growth Rating: 41
Price Growth Rating: 58
SMR Rating: 93
Profit Risk Rating: 87
Seasonality Score: 5 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
Alphabet (GOOGL) fell roughly 15.3% over the last 30 days, sliding from about $349.22 to $295.77, driven primarily by a post-earnings selloff. The decline followed Alphabet's Q3 2026 results, when earnings per share of $2.12 badly missed the $3.02 consensus estimate.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.